PubRank

Steven M Larson

Author PubWeight™ 209.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007 4.42
2 Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005 3.71
3 Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005 3.51
4 Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007 2.83
5 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010 2.82
6 A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003 2.73
7 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004 2.66
8 Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003 2.62
9 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003 2.44
10 Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011 2.42
11 Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med 2003 2.33
12 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2005 2.30
13 A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 2012 2.27
14 Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 2012 2.26
15 Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 2013 2.24
16 Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006 2.24
17 Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun 2013 2.12
18 Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004 2.05
19 Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003 2.04
20 (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med 2011 2.01
21 Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002 1.99
22 Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med 2009 1.98
23 Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005 1.97
24 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011 1.97
25 The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005 1.97
26 Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009 1.97
27 Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 2011 1.91
28 Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005 1.89
29 Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2012 1.87
30 Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003 1.87
31 Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011 1.87
32 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008 1.82
33 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004 1.76
34 Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys 2004 1.74
35 Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 2007 1.72
36 Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007 1.69
37 Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005 1.67
38 Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010 1.67
39 Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002 1.66
40 Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008 1.65
41 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med 2010 1.63
42 Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004 1.60
43 Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002 1.57
44 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005 1.53
45 Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008 1.49
46 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006 1.46
47 The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 2004 1.44
48 Feasibility of ex vivo FDG PET of the colon. Radiology 2009 1.43
49 Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002 1.41
50 Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 2010 1.40
51 Deep-inspiration breath-hold PET/CT of the thorax. J Nucl Med 2007 1.39
52 Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer 2010 1.39
53 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 2011 1.36
54 PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004 1.30
55 Molecular imaging for personalized cancer care. Mol Oncol 2012 1.28
56 Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med 2010 1.27
57 NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007 1.26
58 Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med 2004 1.26
59 Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005 1.26
60 Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002 1.26
61 Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010 1.25
62 Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A 2005 1.24
63 Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 2009 1.23
64 PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004 1.22
65 Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013 1.21
66 FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol 2007 1.20
67 Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013 1.20
68 Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med 2011 1.18
69 Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006 1.18
70 Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010 1.17
71 Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003 1.15
72 Global trends in hybrid imaging. Radiology 2010 1.15
73 Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008 1.15
74 In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res 2007 1.15
75 Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 2006 1.15
76 An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002 1.14
77 Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007 1.14
78 Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003 1.13
79 Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun 2012 1.13
80 ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2014 1.10
81 Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride. J Nucl Med 2013 1.10
82 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006 1.10
83 Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011 1.10
84 Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003 1.09
85 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med 2011 1.08
86 Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 2006 1.08
87 Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006 1.07
88 Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2002 1.07
89 Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004 1.07
90 Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013 1.06
91 Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions. J Nucl Med 2007 1.04
92 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002 1.04
93 Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. AJR Am J Roentgenol 2007 1.03
94 Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecol Oncol 2010 1.03
95 Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009 1.02
96 Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006 1.01
97 Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004 1.00
98 Molecular imaging of prostate cancer. Curr Opin Urol 2012 0.98
99 Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol 2011 0.97
100 Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 2013 0.97
101 Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007 0.97
102 The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med 2010 0.96
103 Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev 2006 0.96
104 Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005 0.95
105 The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 2006 0.95
106 A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes. Surg Endosc 2007 0.95
107 The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 2013 0.95
108 CT in PET/CT: essential features of interpretation. J Nucl Med 2005 0.95
109 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004 0.94
110 Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002 0.94
111 Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm 2005 0.94
112 [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging 2006 0.94
113 Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. Clin Cancer Res 2004 0.93
114 Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. J Nucl Med 2010 0.92
115 Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008 0.92
116 Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med 2008 0.92
117 Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med 2011 0.90
118 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med 2009 0.90
119 Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest 2007 0.90
120 Bone marrow dosimetry using 124I-PET. J Nucl Med 2012 0.90
121 A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 2011 0.89
122 Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol 2005 0.89
123 Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 2012 0.87
124 Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014 0.87
125 PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003 0.86
126 Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 2003 0.85
127 Respiratory artefact causing malpositioning of liver dome lesion in right lower lung. Clin Nucl Med 2003 0.85
128 An analysis of the 18F-FDG uptake pattern in the stomach. J Nucl Med 2005 0.85
129 Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance. Cardiovasc Intervent Radiol 2010 0.85
130 How to assess background activity: introducing a histogram-based analysis as a first step for accurate one-step PET quantification. Nucl Med Commun 2014 0.85
131 In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research. Microvasc Res 2009 0.84
132 Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003 0.84
133 Biomedical imaging research opportunities workshop IV: a white paper. Med Phys 2007 0.83
134 In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med 2011 0.83
135 The value of positron emission tomography (PET) in the management of patients with thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008 0.83
136 FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Dis Colon Rectum 2012 0.82
137 Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging 2013 0.82
138 Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. Eur J Nucl Med Mol Imaging 2010 0.82
139 Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release 2010 0.82
140 Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer. Am J Clin Oncol 2008 0.82
141 The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. Eur J Nucl Med Mol Imaging 2009 0.82
142 Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia 2012 0.81
143 A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003 0.81
144 (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med 2010 0.81
145 Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol 2007 0.80
146 Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol 2005 0.80
147 Portable PET probes are a novel tool for intraoperative localization of tumor deposits. Ann Surg Innov Res 2009 0.80
148 Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med 2013 0.79
149 Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy. Mol Pharm 2013 0.79
150 PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging 2015 0.79
151 A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol 2012 0.78
152 Monoclonal antibody therapy of kidney cancer. Cancer Treat Res 2003 0.78
153 N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein. Bioconjug Chem 2013 0.78
154 Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med 2012 0.78
155 Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 2016 0.77
156 Copper-64 trastuzumab PET imaging: a reproducibility study. Q J Nucl Med Mol Imaging 2016 0.77
157 Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET. Mol Imaging Biol 2013 0.77
158 Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur J Nucl Med Mol Imaging 2010 0.77
159 Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo. Mol Imaging Biol 2013 0.76
160 Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol 2011 0.75
161 Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 2013 0.75
162 Response. Radiology 2015 0.75
163 Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology. J Clin Oncol 2008 0.75
164 JNM supplement on molecular radiotherapy. J Nucl Med 2005 0.75
165 Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications. Health Phys 2009 0.75
166 Challenging cases in thyroid cancer: a multidisciplinary approach. Eur J Nucl Med Mol Imaging 2003 0.75
167 Oncology. J Nucl Med 2011 0.75
168 New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep 2003 0.75
169 What nuclear cardiology can learn from nuclear oncology. J Nucl Cardiol 2003 0.75
170 Components of professional competence for nuclear medicine physicians. J Nucl Med 2003 0.75
171 Oncology. J Nucl Med 2010 0.75